- Trial phase
- Approved (marketed)
- Time to market
- Already on the market, FDA approved oral tablets December 21, 2015, and the IV formulation July 30, 2021; pediatric (2+) labeling added later.
- Why 3/10
- No hard, dated binary catalyst in the next ~12 months: UPTRAVI is already approved and commercializing (last FDA action was a supplemental labeling approval on 2026-05-23), and as one small product inside a mega-cap portfolio it is not a share-price driver for JNJ.
Do not trade JNJ on Uptravi: it is a mature, approved product with no pending regulatory decision and it is immaterial to a ~$262 stock (mean analyst target $272.50 implies only ~7% upside, driven by JNJ's broader pipeline). Treat Uptravi as steady franchise revenue, the meaningful stock drivers are JNJ's oncology/immunology and medtech programs, not PAH.
Price Chart
Executive Summary
UPTRAVI (selexipag), sold by Johnson & Johnson through its Actelion/Janssen unit, is an approved oral (and IV) treatment for pulmonary arterial hypertension, high blood pressure in the lung arteries. The FDA approved it December 21, 2015 after the Phase 3 GRIPHON trial (1,156 patients) showed it cut the risk of disease-progression or hospitalization events by roughly 40% versus placebo, and an IV version was approved July 30, 2021 for patients temporarily unable to take pills. It is a mature commercial product in a competitive niche market and a very small part of a mega-cap company, so it carries no near-term regulatory binary for JNJ stock.
How It Works
Selexipag is a pill (and an IV infusion) that mimics a natural blood-vessel-signaling molecule, prostacyclin, by activating "IP receptors" on the walls of lung arteries. That signal relaxes and widens the arteries, lowering the high blood pressure in the lungs that defines pulmonary arterial hypertension (PAH). The body converts the pill into an active form that does the receptor work.
Trial Status
Approved on the strength of the Phase 3 GRIPHON study (1,156 patients with symptomatic PAH), which showed a ~40% reduction in risk of a morbidity/mortality event vs placebo; an IV formulation was approved in 2021; the label now covers adults and children 2+; a supplemental FDA action (labeling, POWDER) was recorded 2026-05-23. A small Phase 2 study of selexipag in Raynaud's phenomenon (Actelion, NCT02260557, n=74) completed without posted results.
The Two-Sided Case
Upcoming Catalysts
- No scheduled regulatory binary for Uptravi in the next ~12 months; watch JNJ quarterly earnings for the Uptravi sales line
- Any generic/selexipag entry or patent-expiry news would be the main long-term commercial event
- Minor: results status of the completed Phase 2 Raynaud's study (NCT02260557), which has no commercial bearing on PAH
Source Filing
The SecBot filing or press-release report that triggered this drug report:
JOHNSON & JOHNSON 8-K JNJ ·Originating report